Statement on the Bipartisan Infrastructure Act

Today, PILMA released the following statement applauding the passage of the Bipartisan Infrastructure Act November 6, 2021 Download the full statement here. PILMA commends Congress for passing landmark legislation that will put union men and women to work updating our nation’s infrastructure. This bill will put the safest, best trained, and highest-skilled workers on the […]

USTR Letter: WTO TRIPS

View letter from PILMA Executive Director, Tim Dickson   October 22, 2021Katherine TaiUnited States Trade Representative600 17th Street, NWWashington, DC 20508   Dear Ambassador Tai, On behalf of the Pharmaceutical Industry Labor-Management Association (PILMA), which advances the dual goals of fostering innovation of life-saving cures and securing high-quality union construction jobs, I write to reiterate […]

Statement on WTO TRIPS Intellectual Property Waiver

On May 6, 2021, PILMA released the following statement on the far reaching negative impacts of the U.S. signing on to the WTO TRIPS waiver. Download the statement here. May 6, 2021 The U.S. Trade Representative’s decision to support waiving intellectual property protections for the COVID-19 vaccine is a danger to worldwide health and security, […]

USTR Letter: PILMA Supports Protection of Intellectual Property Rights

On March 1, 2021, General President of SMART and PILMA Chairman Joseph Sellers, Jr. sent the following letter to the Acting U.S. Trade Representative Maria L. Pagan urging continued protections of intellectual property: View letter from President Sellers. View letter from PILMA Executive Director Timothy Dickson. March 1, 2021Maria L. PaganActing United States Trade Representative600 […]

Data shows half of all spending on brand medicines is retained by manufacturer

Last year, PILMA in collaboration with union health care and benefits expert Randy DeFrehn released a report titled “An Understanding and Implications of the Cost Drivers in the Drug Supply Chain.” PILMA combined DeFrehn’s findings with data from a new report by Berkeley Research Group to extrapolate on the original report and provide insight into which entities in the supply chain are receiving an increasing share of revenue from prescription medicines.

PILMA Chairman Issues Statement on Legislative Proposals that would Harm Innovation and Jobs

On January 16, 2019, Eric Dean, General President of the International Association of Bridge, Structural, Ornamental and Reinforcing Iron Workers and Chairman of PILMA issued the following statement on legislative proposals that would negatively impact innovation and jobs. View the statement in PDF.  The biopharmaceutical industry supports more than 4.7 million American jobs.  Significant investment in capital […]

PILMA Statement on HHS Speech and its Impact on Innovation and Union Jobs

On October 25, 2018, PILMA released the following statement in response to President Trump’s speech at the Department of Health and Human Services. The statement follows a previously adopted PILMA Resolution on Price Controls. View the statement in PDF.  The labor unions and biopharmaceutical companies of the Pharmaceutical Industry Labor-Management Association (PILMA) have a longstanding […]

LillyPad: What Does IP Have to Do With Union Construction Jobs?

The following post appeared on LillyPad.  By: Eric Dean, General President of the International Association of Bridge, Structural, Ornamental and Reinforcing Iron Workers and Chairman of the Pharmaceutical Industry Labor-Management Association (PILMA). At the intersection between the biopharmaceutical industry and North America’s Building Trades Unions is thePharmaceutical Industry Labor-Management Association, better known as PILMA. As Chairman […]

Statement by SMART General President Joseph Sellers On President Trump’s Drug Pricing Speech

Download the statement here. WASHINGTON (May 23, 2018) – Joseph Sellers, General President of SMART, the International Association of Sheet Metal, Air, Rail and Transportation Workers, released the following statement in response to President Trump’s speech on drug prices: “We commend the Trump Administration for the attention on this critical issue, particularly the much-needed focus […]